Ovagen 20 mg

DRAGON PHARMA OVAGEN

Dragon Pharma Ovagen 20mg represents a cutting-edge advancement in organ-protective peptide therapy, specifically engineered for athletes and bodybuilders facing hepatic and gastrointestinal stress from intense training, supplementation, and performance-enhancing compounds. As a tripeptide bioregulator derived from the pioneering research of Professor Vladimir Khavinson, Ovagen targets cellular repair mechanisms in liver and intestinal tissues. This 20mg lyophilized formulation offers concentrated support for individuals using hepatotoxic oral steroids, experiencing GI distress from extreme nutrition protocols, or seeking to enhance organ resilience during demanding athletic cycles.

DRUG COMPOSITION

Each 2mL vial contains 20mg of Ovagen (Lys-Glu-Asp), a synthetic tripeptide identical to the natural liver cytomedin. The molecular formula is C₁₄H₂₄N₄O₈ with a molecular weight of 376.36 g/mol. Dragon Pharma's manufacturing utilizes solid-phase peptide synthesis followed by HPLC purification to achieve ≥98% purity. The lyophilized powder contains no preservatives, stabilizers, or bacterial endotoxins. The tripeptide sequence (Lysine-Glutamic Acid-Aspartic Acid) represents the minimal active fragment of liver tissue-specific peptide bioregulators identified in Khavinson's research.

PHARMACEUTICAL FORM

Sterile, white to off-white lyophilized powder in a 2mL borosilicate glass vial sealed with a bromobutyl rubber stopper and aluminum crimp cap. The powder exhibits excellent solubility in bacteriostatic water or sterile saline, dissolving completely within 30 seconds of gentle swirling. Lyophilization ensures extended stability at refrigerator temperatures compared to liquid peptide formulations. Each vial contains a slight overfill to guarantee delivery of the full 20mg dose after reconstitution.

PHARMACEUTICAL GROUP AND ATC CODE

Ovagen belongs to the therapeutic category "Other alimentary tract and metabolism products" (A16AX). More specifically, it's classified as a peptide bioregulator or cytomedin. These compounds represent a novel class of tissue-specific peptides that regulate gene expression and protein synthesis in their target organs. Unlike general hepatoprotectants like silymarin or ursodeoxycholic acid (A05BA), Ovagen exhibits tissue-specific action on liver parenchymal cells and gastrointestinal mucosal epithelium through epigenetic modulation.

PHARMACOLOGICAL PROPERTIES

Ovagen operates through a unique epigenetic mechanism, modulating gene expression in liver and gastrointestinal tissues without direct receptor agonism. The tripeptide enters target cells via peptide transporters and influences chromatin structure, particularly affecting genes involved in cellular repair, antioxidant defense, and apoptosis regulation. Research indicates Ovagen upregulates expression of heat shock proteins (HSP70) and downregulates pro-fibrotic TGF-β signaling pathways. According to studies published in Biogerontology, Khavinson peptides like Ovagen can increase maximum lifespan in animal models by enhancing organ-specific resilience and reducing age-related pathology. In liver tissue, Ovagen stimulates hepatocyte proliferation while inhibiting stellate cell activation, potentially reversing early fibrotic changes. In the GI tract, it enhances mucosal barrier function by upregulating tight junction proteins and mucin production.

THERAPEUTICAL INDICATIONS

Dragon Pharma Ovagen 20mg is indicated for research into:

1. Hepatoprotection during use of oral anabolic steroids (particularly 17α-alkylated compounds)
2. Gastrointestinal mucosal repair during extreme calorie or protein intake phases
3. Prevention and potential reversal of early-stage hepatic fibrosis
4. Support during post-cycle therapy when liver enzymes may be elevated
5. Protection against environmental hepatotoxins (alcohol, medications, pollutants)
6. Enhanced recovery from intense training through improved nutrient absorption
7. Potential adjunctive support for HIV-related complications (research interest)

For bodybuilders, Ovagen is particularly valuable during oral steroid cycles, when liver stress is maximal, and during contest preparation when GI integrity may be compromised by extreme dieting and fat-loss compounds.

DOSES AND METHOD OF ADMINISTRATION

Reconstitution: Add 2mL of bacteriostatic water or sterile saline to the 20mg vial. Gently swirl until completely dissolved. The resulting concentration is 10mg/mL. For precise dosing, insulin syringes (0.3mL or 0.5mL capacity) are recommended.

Administration: Subcutaneous injection is the standard route. Some research suggests sublingual administration may have efficacy due to peptide stability in oral mucosa, but bioavailability is approximately 40% compared to 95% for subcutaneous.

Dosing Protocol:

• Standard research dose: 5-10mg (0.5-1.0mL of 10mg/mL solution) every 2-3 days
• During oral steroid cycles: 10mg every other day throughout cycle duration
• PCT/recovery phase: 5mg twice weekly for 4-6 weeks
• Preventive maintenance: 5mg once weekly
• Maximum research dose: 20mg daily (short-term only, under supervision)

Inject subcutaneously in abdominal or thigh tissue, rotating sites. Effects are cumulative over 2-4 weeks. For optimal results, use consistently for minimum 30-day periods.

CYCLE/STACKING

Ovagen synergizes effectively with several Dragon Pharma products to enhance performance while mitigating organ stress:

1. With oral hepatotoxic steroids like Anadrol Inj 50 or Dianabol 50: Ovagen provides essential hepatic protection during cycles with 17α-alkylated compounds, potentially allowing longer or more effective oral phases while monitoring liver enzymes.
2. With BPC-157: This combination offers comprehensive GI protection and repair. While BPC-157 addresses ulceration and inflammation, Ovagen enhances mucosal barrier function and nutrient absorption—ideal for athletes with demanding diets.
3. With TB-500 (Thymosin Beta-4): For comprehensive tissue repair, TB-500 addresses musculoskeletal injuries while Ovagen protects internal organs. This stack is particularly valuable during intense training phases.
4. With Aromasin (Exemestane): During estrogen-control phases, Ovagen may help protect hepatic estrogen metabolism pathways while Aromasin controls circulating estrogen levels.
5. With GHK-cu 50 mg: This copper peptide combination addresses systemic aging and repair. GHK-cu enhances skin and connective tissue while Ovagen focuses on internal organ resilience.

POST CYCLE THERAPY

Ovagen plays a crucial role in post-cycle recovery by supporting liver regeneration and restoring optimal digestive function. After anabolic steroid cycles—particularly those involving oral compounds—the liver requires significant support to regenerate damaged hepatocytes and normalize enzyme levels. Ovagen accelerates this process through its epigenetic modulation of repair pathways. During PCT with SERMs like Clomid or Nolvadex, include Ovagen at 5-10mg twice weekly for 4-6 weeks. This not only aids hepatic recovery but also enhances nutrient absorption crucial for maintaining gains during the hormonal transition period. Athletes report better appetite, reduced bloating, and improved digestion when incorporating Ovagen into their PCT protocol.

SIDE EFFECTS

Ovagen exhibits an exceptional safety profile with minimal reported adverse effects:

• Very rare (<0.1%): Mild injection site reactions (redness, itching)
• Extremely rare: Transient headache or mild fatigue after first administration
• No reports of: Hormonal disruption, blood pressure changes, or psychological effects
• Theoretical concerns: Overstimulation of repair pathways in pre-existing malignancies (though research suggests cytomedins are tissue-stabilizing rather than proliferative)

In decades of Khavinson peptide research, no serious adverse events have been documented at therapeutic doses. The peptide's high tissue specificity and natural derivation contribute to its favorable safety profile. However, as with any bioactive peptide, individual sensitivity cannot be entirely ruled out.

CONTRAINDICATIONS

While Ovagen has broad compatibility, theoretical contraindications include:

1. Active hepatic malignancies (theoretical concern about growth stimulation)
2. Acute hepatic failure (due to lack of research in critical conditions)
3. Known hypersensitivity to the peptide or its components
4. Pregnancy and lactation (insufficient safety data)
5. Concurrent use with immunosuppressive therapy in transplant patients
6. Severe renal impairment (though peptide is metabolized hepatically)

Notably, Ovagen appears safe with most medications and supplements commonly used by athletes, including AAS, SARMs, nootropics, and cardiovascular support compounds.

OVERDOSE

No cases of Ovagen overdose have been reported in the research literature. Animal studies using doses up to 100 times the therapeutic equivalent (approximately 200mg for a human) showed no acute toxicity. The peptide appears to have a wide therapeutic window due to its tissue-specific action and natural degradation pathways. In case of accidental extreme overdose, standard supportive measures are recommended. The peptide is rapidly cleared via hepatic metabolism and renal excretion, with complete elimination within 24 hours even at supraphysiological doses.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

1. Monitoring requirements: Regular liver function tests (ALT, AST, GGT) are recommended during use, especially when stacked with hepatotoxic compounds.
2. Cancer screening: Individuals with personal or family history of hepatic or gastrointestinal malignancies should consult healthcare providers before use.
3. Autoimmune conditions: Theoretical concern about immune modulation; monitor autoimmune markers if applicable.
4. Athlete considerations: Ovagen is not a substitute for responsible steroid use, proper cycle planning, or medical supervision.
5. Reconstitution hygiene: Strict aseptic technique must be maintained to prevent bacterial contamination.
6. Storage compliance: Refrigeration is essential for maintaining peptide stability and potency.
7. Realistic expectations: While protective, Ovagen cannot completely eliminate risks from extreme compound use or poor lifestyle choices.

INTERACTIONS WITH OTHER DRUGS

1. Hepatotoxic medications: Ovagen may reduce liver injury from compounds like oral steroids, acetaminophen, anticonvulsants, and certain antibiotics.
2. Chemotherapy agents: Research suggests protective effects against GI mucosal damage from agents like 5-FU and methotrexate.
3. Alcohol: May mitigate some hepatic effects of ethanol consumption, but not a license for excessive drinking.
4. Other peptides: Synergistic with BPC-157, TB-500, and GHK-cu for comprehensive tissue support.
5. Nootropics/Cognitive enhancers: No known interactions; may actually support liver metabolism of these compounds.
6. HIV medications: Early research suggests potential adjunctive benefits, but clinical data is limited.

Notably, Ovagen does not appear to affect the pharmacokinetics or efficacy of anabolic steroids, making it ideal for concurrent use.

PRESENTATION, PACKAGING

Dragon Pharma Ovagen 20mg is supplied as a single 2mL glass vial containing white lyophilized powder. Each vial is individually packaged in a sealed aluminum pouch with desiccant to maintain stability. The outer box displays product information, batch number, expiration date, and Dragon Pharma hologram for authenticity verification. Research quantities (5, 10, and 20 vial packs) are available for extended protocols. All packaging is discreet and unmarked for privacy during shipping.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in their original packaging protected from light. Avoid freezing the lyophilized powder. Once reconstituted, store solution at 2-8°C and use within 30 days. Do not expose to temperatures above 25°C (77°F) for extended periods. For long-term storage of unopened vials (beyond expiration date), -20°C is acceptable but not required. Always check reconstituted solution for clarity before use—discard if cloudy or containing particles.

DELIVERY TO THE USA

Dragon Pharma ships Ovagen 20mg discreetly to all 50 states via domestic reshipping services that minimize customs scrutiny. Orders are processed within 24-48 hours and typically delivered within 3-7 business days via USPS Priority or private courier. Tracking information is provided upon shipment. Packaging is plain and unmarked for privacy. The product is sold for research purposes only in accordance with FDA regulations regarding peptide distribution.

LEGAL STATUS

In the United States, Ovagen is classified as a research chemical peptide, not approved by the FDA for any therapeutic indication. It is sold for laboratory research purposes only under the provision of Section 201(ff) of the Federal Food, Drug, and Cosmetic Act. It is not a controlled substance under the CSA. Purchasers assume full responsibility for compliance with local regulations. Athletes should note that while not explicitly banned by most sports organizations, peptides may fall under general prohibitions against performance-enhancing methods.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• Khavinson Peptides: Mechanisms and Clinical Applications Review
• Liver-Targeted Peptide Bioregulators in Age-Related Pathology

PROFILE

• Chemical name: L-Lysyl-L-α-glutamyl-L-α-aspartic acid
• Chemical formula: C₁₄H₂₄N₄O₈
• Percentage of anabolic activity: 0% (non-hormonal peptide)
• Percentage of androgenic activity: 0% (non-androgenic)
• Active half life: 2-4 hours (plasma); epigenetic effects last 48-72 hours
• Recommended dosage: 5-10mg every 2-3 days subcutaneously
• Acne: Not associated
• Bloating (water retention): May actually reduce GI-related bloating
• HBR: Hepatobiliary reactions not reported; protective effects documented
• Hepatic toxicity: None; demonstrates hepatoprotective properties
• Aromatization: Does not aromatize